Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06841679 is registered in ClinicalTrials.gov with Beijing Biostar Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06841679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06841679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 28, 2025
Completion date
September 1, 2030
Enrollment
778 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or gastroesophageal junction adenocarcinoma